Moderna, Inc.

The stock is still in a long recovery regime, trading well above its 200-day moving average after a deep 52-week drawdown. The setup is constructive but extended versus the low, with the chart now working through a broad rebound rather than a fresh base.

Street sentiment is cautious-to-neutral: the consensus sits at Hold, and the average target of 46.5 is well below the last close. Recent target moves have trended higher, but most firms still sit on hold-style ratings, so upside depends on execution rather than multiple expansion alone.

The next print comes after a mixed beat/miss run, with 5 beats in the last 7 quarters but a sharp miss in the prior quarter. Estimates still point to losses, with 2027 EPS at -4.75 and 2028 at -2.74, so shareholders should watch for margin discipline and cash-burn improvement.

The tape shows net selling, led by Stephen Hoge’s June sale, while most other recent moves are awards, exempt exercises, or withholding-related activity. Those non-discretionary flows are noise; the only clear discretionary signal in the period is the president’s sale.

Profitability remains weak, with a -69.9% gross margin and a -131.1% operating margin. Revenue is still growing 260.2% year over year, but free cash flow was -$1.68 billion and EPS TTM is -7.26, so the balance sheet and cash runway matter more than near-term earnings power.

Moderna still screens as a high-beta biotech with a 0.942 beta and a valuation anchored to pipeline execution rather than current earnings. Versus peers, the market is paying for optionality, but the stock trades at a discount to the average target and needs clearer commercialization traction to rerate.